Fig. 6

ADV-ApoA1 inhibits TNBC growth in mouse models. (a) Scheme of the adenovirus backbone for ADV-ApoA1 and ADV-Ctrl. (b) and (c) Expression of ApoA1 in the supernatant of culture media from 4T1 and MDA-MB-231 cells infected with ADV-ApoA1 and ADV-Ctrl detected using ELISA. (d) to f) Quantification of the replication ability of ADV-ApoA1 and ADV-Ctrl in 4T1, MDA-MB-231, and HCC1937 cells using qPCR. g) 4T1 cells infected with ADV-ApoA1 or ADV-Ctrl for 48 h, and intracellular cholesterol stained with filipin. h) 4T1 and HCC1937 cells transfected with E1A encoding plasmid in vitro, and mRNA levels of ABCA1 determined by qPCR. i) Treatment scheme of the 4T1 orthotopic breast cancer model. j) and k) Tumor volume curve and survival of mice treated with oncolytic virus. l) Estimation of immune cell infiltration using the ssGSEA method. m) Expression of nFOXO3a, p-IκB, p65, and KRT14 in 4T1 orthotopic tumors treated with PBS, ADV-Ctr, or ADV-ApoA1. n) Tumor volume of nude mice with an orthotopic MDA-MB-231 breast cancer model, which was established and treated similar to 4T1 orthotopic breast cancer model. o) Treatment scheme of the humanized orthotopic MDA-MB-231 breast cancer model in NCG mice. p) Tumor volume curve of mice treated with oncolytic virus. n.s.: no significant difference; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001